This is stated in the message of the Beijing Institute of Biological Products, which is part of Sinopharm.

"After two injections, the vaccinated developed antibodies with a high titer, the protective efficacy of the vaccine against COVID-19 was 79.34%," RIA Novosti was quoted as saying.

It is specified that these are interim results of the third stage of clinical trials of a Chinese vaccine. 

In November, it was reported that about 1 million people were vaccinated with the Sinopharm vaccine.